- Home
- EML vs ATOS Comparison
EML vs ATOS Comparison
Compare EML & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ATOS
- Stock Information
- Founded
- EML 1858
- ATOS 2009
- Country
- EML United States
- ATOS United States
- Employees
- EML N/A
- ATOS N/A
- Industry
- EML Industrial Machinery/Components
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- ATOS Health Care
- Exchange
- EML Nasdaq
- ATOS Nasdaq
- Market Cap
- EML N/A
- ATOS 174.8M
- IPO Year
- EML N/A
- ATOS 2012
- Fundamental
- Price
- EML $31.49
- ATOS $1.41
- Analyst Decision
- EML
- ATOS Strong Buy
- Analyst Count
- EML 0
- ATOS 3
- Target Price
- EML N/A
- ATOS $6.25
- AVG Volume (30 Days)
- EML 35.1K
- ATOS 578.3K
- Earning Date
- EML 11-05-2024
- ATOS 11-12-2024
- Dividend Yield
- EML 1.35%
- ATOS N/A
- EPS Growth
- EML 65.47
- ATOS N/A
- EPS
- EML 1.92
- ATOS N/A
- Revenue
- EML $273,702,675.00
- ATOS N/A
- Revenue This Year
- EML N/A
- ATOS N/A
- Revenue Next Year
- EML N/A
- ATOS N/A
- P/E Ratio
- EML $16.90
- ATOS N/A
- Revenue Growth
- EML N/A
- ATOS N/A
- 52 Week Low
- EML $16.10
- ATOS $0.62
- 52 Week High
- EML $35.78
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- EML 52.56
- ATOS 48.63
- Support Level
- EML $31.50
- ATOS $1.35
- Resistance Level
- EML $33.00
- ATOS $1.58
- Average True Range (ATR)
- EML 1.24
- ATOS 0.08
- MACD
- EML -0.04
- ATOS -0.01
- Stochastic Oscillator
- EML 44.78
- ATOS 26.09
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.